

Haematologica
HAEMATOL/2015/140988
Version 3

A randomised phase II trial of azacitidine +/- epoetin beta In lower risk myelodysplastic syndromes if resistant to erythropoietic stimulating agents

Sylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, Aline Renneville, Odile Beyne-Rauzy, Thomas Prébet, Sophie Park, Aspasia Stamatoullas, Agnes Guerci-Bresler, Stéphane Cheze, Gérard Tertian, Bachra Choufi, Laurence Legros, Jean Noel Bastié, Jacques Delaunay, Marie Pierre Chaury, Laurence Sanhes, Eric Wattel, Francois Dreyfus, Norbert Vey, Fatiha Chermat, Claude Preudhomme, Pierre Fenaux, and Claude Gardin

Disclosures: none

Contributions: ST/CG performed clinical research RBA/AR/CP performed biological research SC performed data analysis ST/RBA/CG/PF/SC wrote manuscript ST/OBR/TP/SP/AS/AGB/SC/GT/BC/LL/JNB/JD/MPC/LS/EN/FD/NV/PF/CG included patients ST and RBA contributed equally to this work